Frazier Life Sciences Management’s Cerevel Therapeutics Holdings CERE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-393,000
Closed -$16.1M – 57
2024
Q2
$16.1M Hold
393,000
– – 0.75% 30
2024
Q1
$16.6M Hold
393,000
– – 0.7% 33
2023
Q4
$16.7M Hold
393,000
– – 0.89% 30
2023
Q3
$8.58M Hold
393,000
– – 0.57% 34
2023
Q2
$12.5M Hold
393,000
– – 0.75% 30
2023
Q1
$9.6M Hold
393,000
– – 0.69% 30
2022
Q4
$12.4M Hold
393,000
– – 0.77% 26
2022
Q3
$11.1M Buy
393,000
+190,740
+94% +$5.68M 0.86% 28
2022
Q2
$5.35M Buy
202,260
+146,425
+262% +$4.16M 0.5% 32
2022
Q1
$1.96M Buy
+55,835
New +$1.63M 0.17% 40

Other funds holding CERE

Frazier Life Sciences Management's CERE Position: Q3 2024 in Review

Frazier Life Sciences Management sold out of Cerevel Therapeutics Holdings (CERE) in Q3 2024, closing a stake of 393,000 shares — an estimated $16.1M sold.

Frazier Life Sciences Management first reported a position in CERE in Q1 2022 and held it in 10 quarters. The position peaked at $16.7M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Frazier Life Sciences Management reported no remaining Cerevel Therapeutics Holdings position as of Q3 2024 after selling out during the quarter.
  • Frazier Life Sciences Management sold 393,000 Cerevel Therapeutics Holdings shares in Q3 2024, an estimated $16.1M.
  • Frazier Life Sciences Management first reported a position in Cerevel Therapeutics Holdings in Q1 2022 and held it in 10 quarters.
  • Frazier Life Sciences Management's Cerevel Therapeutics Holdings position peaked at $16.7M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings as of Q3 2024.

Based on Frazier Life Sciences Management's 13F filing for Q3 2024, filed 15 Nov 2024.